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Abstract 
Purpose: To evaluate the characteristics and racial variations amongst patients with polypoidal choroidal vasculopa-
thy (PCV) in the United States and the United Kingdom.
Methods: Fundus photos and indocyanine green angiography images were evaluated in a multicenter retrospective 
study to establish the diagnosis of PCV. Visual acuity (VA) was recorded in ETDRS letter count.
Results: Eighty eyes of 71 PCV patients (average age of 69.4 ± 10.4 years) were included in the analysis. Of the total 
71 subjects, 46 (65%) were women, 33 (46.5%) were Blacks, 16 (22.5%) were Whites, 19 (26.8%) were Asians and 3 
(4.2%) belonged to other races. The Black subgroup had vision gain of 3.5 letters. The White and Asian subgroups had 
vision loss of 13.1 and 3.5 letters, respectively. There was female predominance in Blacks (67%), Whites (69%), and 
Asians (58%). PCV was found to be a bilateral disease in 14 patients (20%). There was significant decrease of 7 letters 
with every decade increase in age (p = 0.005). Final VA was worse in males when compared to females (p = 0.042), 
and worse in Whites when compared to Blacks (p = 0.005). For every 10 letters worse in initial VA upon diagnosis with 
PCV, the final VA was worse by 6 letters (p < 0.001). The location of the polypoidal lesion within the macula was associ-
ated with significant decrease of 14 letters in BCVA (p = 0.02). The length of follow up was significantly associated 
with worse visual outcome (p = 0.012). Final VA had no significant correlation with the lens status, or the different 
treatment modalities.
Conclusions: Based on our cohort from tertiary centers in the United States and United Kingdom, PCV is a bilateral 
disease in one-fifth of patients. It features a variable female predominance based on ethnicity. Increased age, worse 
vision upon initial presentation, longer follow up and macular location of the polyp were associated with worse visual 
outcome.
Keywords: Polypoidal choroidal vasculopathy (PCV), Indocyanine green angiography (ICGA), Fluorescein 
angiography (FA), Optical coherence tomography (OCT)
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Background
Polypoidal choroidal vasculopathy (PCV) is a distinct 
clinical entity that is associated with abnormal inner 
choroidal vascular network of vessels ending in an aneu-
rysmal projection, visible clinically in some cases as 
orange reddish spheroid polyp-like structures [1]. PCV 
is characterized by multiple, recurrent, serosanguinous 
detachments of the retinal pigment epithelium and neu-
rosensory retina secondary to leakage and bleeding from 
the polypoidal lesions [1, 2].
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Most of the large PCV studies come from Japan, 
South Korea and Singapore, where the disease has been 
reported to be more prevalent. Japanese studies have 
shown that one-fourth to one half of the elderly patients 
with neovascular age-related macular degeneration 
(AMD) in Japan were diagnosed with PCV [3, 4]. How-
ever, individuals of other ethnicities may develop PCV as 
well. Lafaut et al. [5] reported ICGA-confirmed PCV in 
4% of white patients with occult choroidal neovasculari-
zation. Recently, a Swiss study revealed PCV in 16.8% of 
Caucasian patients with neovascular AMD [6].
Indocyanine green angiography (ICGA) remains the 
gold standard in establishing the diagnosis of PCV, 
because it can demonstrate the polypoidal lesions and the 
branching vascular network underneath the RPE, which 
can be missed using standard fluorescein angiography [7]. 
However, it is important to realize that not all focal sub-
retinal nodular hyperfluorescence on ICGA is presumed 
to be due to polyps. Therefore, the EVEREST study report 
2 described the imaging and grading protocols to stand-
ardize the diagnostic criteria for future randomized con-
trolled trials on PCV [8]. Multiple reports have described 
the optical coherence tomography (OCT) features of PCV 
and correlated them with ICGA findings [9–17].
The natural course of PCV usually follows a relapsing-
remitting course, where the visual outcome can vary. 
Uyama et al. [18] followed 14 eyes of 12 patients with PCV 
for 2  years without any treatment. A favorable outcome 
was noted in 50% of patients, whereas the remaining half 
suffered from persistence of the disease and repeated sero-
sanguinous leakage, resulting in unfavorable visual out-
come. On the other hand, the treatment guidelines for PCV 
were established by the Everest Study Group (a prospec-
tive multicenter randomized controlled clinical trial, which 
included 61 Asian patients) which recommended treat-
ment of juxtafoveal and subfoveal PCV with ICGA-guided 
photodynamic therapy (PDT) or PDT plus 3 ranibizumab 
intravitreal injections 1 month apart [19, 20]. Recent stud-
ies have observed and reported resistance to ranibizumab 
in some patients with PCV [21, 22]. There have been recent 
studies from Japan reporting the use of aflibercept in PCV 
patients, who are naïve to treatment or not responding to 
ranibizumab [23–25]. The long term behavior of visual acu-
ity (VA) in PCV patients of different ethnicities remains 
controversial and further studies are warranted. Our study 
describes the characteristics and visual outcomes in PCV 
patients of different ethnicities from three tertiary centers 
in the United States and the United Kingdom.
Methods
Data collection
We retrospectively reviewed the records of patients with 
PCV at Yale Eye Center, Moorfields Eye Hospital and 
New England Eye Center between September 2005 and 
December 2015. Study protocols were approved by the 
Institutional Review Board at Yale University and Tufts 
University and were in accordance with the Health Insur-
ance Portability and Accountability Act. The research 
adhered to the tenets of the Declaration of Helsinki for 
research involving human subjects.
After comprehensive chart review, 155 eyes with PCV 
were identified in a retrospective multicenter study. The 
VA score from the United Kingdom (Moorfields) was 
recorded using the Early Treatment Diabetic Retinopa-
thy Study (ETDRS) letter count. The VA score from the 
United States centers (Tufts University and Yale Univer-
sity) was recorded using Snellen charts, then converted 
to ETDRS letter count using a conversion chart. The VA 
for all patients was documented at baseline and last fol-
low up visit. Age at the time of initial diagnosis, ethnicity, 
and lens status (phakic versus pseudophakic) were docu-
mented. Dilated fundus examination findings and color 
fundus photography images were reviewed. Patients with 
concurrent retinal pathologies were excluded from the 
analysis.
PCV diagnosis was confirmed based on the EVER-
EST definition [8, 26, 27], including the presence of early 
focal subretinal hyperfluorescence on ICGA and at least 
one of the following six diagnostic criteria: (1) nodular 
appearance of polyp(s) on stereoscopic examination, (2) 
hypofluorescent halo around nodule(s), (3) presence of 
a branching vascular network, (4) Pulsatile filling of the 
polyps on dynamic ICGA, (5) orange subretinal nodules 
on color fundus photography, or (6) massive submacu-
lar hemorrhage (≥4 disc areas in size). Figures 1, 2 3 and 
Additional file  1: Video 1 further demonstrate some of 
the aforementioned diagnostic features.  
ICGA confirmed the presence of the polyps (Figs. 1, 4, 
5, 6). The location of the polyps was recorded as either 
macular or extra-macular (based on the anatomical mac-
ula with a diameter of 5.5 mm centered at the fovea). In 
eyes where both macular and extramacular polypoidal 
lesions were observed simultaneously, eyes were labeled 
as having macular polypoidal lesions (Fig.  4). OCT 
images were evaluated for the following features: pig-
ment epithelial detachment (PED), subretinal fluid (SRF), 
branching vascular network (BVN) and intraretinal fluid 
(IRF). Figures 1, 3, 4, 6 show some of the abovementioned 
OCT features.
History of previous treatments with focal laser, PDT, 
intravitreal injections with anti-VEGF agents (bevaci-
zumab, ranibizumab and aflibercept) were quantified and 
recorded in a chronological order.
Morphological features of PCV were identified by 2 
independent authors (TA and NM) using a standard 
protocol to analyze color photographs, ICGA and OCT 
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images. Disagreement between the two observers was 
resolved by open adjudication.
Statistical methods
The variables data are presented as mean  ±  standard 
deviation. Multivariate analysis model was performed 
to determine the effects of age, gender, ethnicity, BCVA 
upon initial presentation, length of follow up, and differ-
ent treatment modalities on the final BCVA in patients 
with PCV. p values of <0.05 were considered statistically 
significant.
Results
Patient characteristics
The 71 subjects included in the study had an average age 
of 69.4 ± 10.4 years (range 50–90 years old). Forty-seven 
subjects were from the United Kingdom (where VA was 
reported in ETDRS letter count), and 24 subjects were 
from the United States (where VA was reported in Snel-
len charts and converted to ETDRS letter count). The 
mean follow-up for the patients was 31.8 ± 27.9 months 
(range 2–120 months). Of the total 71 subjects, 46 (65%) 
were women, 33 (46.5%) were Blacks, 16 (22.5%) were 
Whites, 19 (26.8%) were Asians and 3 (4.2%) belonged to 
other races (Table 1). Out of the total 80 eyes included in 
the analysis, there were 38 right eyes and 42 left eyes.
Location of the polypoidal lesions
Out of the total 80 eyes, 62 eyes had macular polypoidal 
lesions and 18 eyes had extra-macular lesions. Macular 
polypoidal lesions were observed in 25 out of 36 black 
eyes (69.4%), 18 out of 23 Asian eyes (78.3%), 16 out of 
19 white eyes (84.2%) and in all 3 eyes of undocumented 
ethnicity. Those findings are summarized in Table 2.
Fig. 1 The EVEREST study diagnostic criteria for polypoidal choroidal vasculopathy. Upper row Color fundus photograph of the left eye of a 71 year 
old Asian man shows nodular appearance of the central macular polyp. Cross-sectional OCT shows central pigment epithelial detachment (where 
the polyp is located) with surrounding subretinal fluid. Bottom row Early and late frames from dynamic indocyanine green angiography (ICGA) show 
progressive filling of the central polyps and hypofluorescent halo around the polyp. Additional file 1: Video 1 demonstrates the dynamic ICGA
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Fig. 2 The EVEREST study diagnostic criteria for polypoidal choroidal vasculopathy. Color Fundus photograph of the left eye of a 61 year old Asian 
female shows orange subretinal nodular appearance of a central macular polyp (superior to the fovea). Early indocyanine green angiography shows 
partial filling of the polypoidal lesion, hypofluorescent halo around the polyp, and a branching vascular network (inferior to the polyp). The branch-
ing vascular network (red aquare) is further demonstrated using AngioVue optical coherence tomography angiography system (Optovue, Inc, 
Fremont, CA); en face images of the choriocapillaris slab
Fig. 3 The EVEREST study diagnostic criteria for polypoidal choroidal vasculopathy. Color fundus photograph of the right eye of a 56 year old Black 
man shows massive submacular hemorrhage (≥4 disc areas in size). Corresponding cross-sectional optical coherence tomography shows large pig-
ment epithelial detachment along the temporal macula consistent with sub-macular hemorrhage
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Optical coherence tomography imaging
Seventy-five eyes out of the total 80 eyes had OCT 
images that were available for analysis. Sixty-six eyes had 
either time-domain or spectral-domain OCT imaging, 
7 eyes had prototype swept source OCT imaging and 2 
eyes had AngioVue OCT angiography (Optovue, Inc, Fre-
mont, CA). Out of the 75 eyes that had OCT imaging, 71 
eyes had PED, 29 eyes had BVN, 65 eyes had SRF, and 18 
eyes had IRF.
Bilateral polypoidal choroidal vasculopathy
Based on ICGA findings in our study, and applying the 
abovementioned EVEREST study definitions, PCV was 
found to be a bilateral disease in 14/71 patients (20%). 
Out of the remaining 57 subjects with presumed unilat-
eral PCV, one Asian patient had her fellow eye enucle-
ated after a non-traumatic massive retinal hemorrhage, 
and another Asian patient had no light perception in 
her fellow eye (phthisis bulbi after untreated chronic 
hemorrhagic retinal detachment). Bilateral PCV was 
noted in 7/33 Black subjects (21%), 3/16 White subjects 
(19%) and 4/19 Asian subjects (21%). Table 2 summarizes 
these findings.
Treatment
Five out of 80 eyes received no treatment at all (two 
eyes of two black patients gained 7 and 9 ETDRS letters 
respectively, 2 eyes of 2 white patients had no change 
in VA, and one eye of undocumented ethnicity lost 9 
ETDRS letters at last follow up). Out of the remaining 
75 eyes, 68 eyes received one or more intravitreal injec-
tions with anti-vascular endothelial growth factor agents 
(bevacizumab, ranibizumab, and or aflibercept). Twelve 
out of 75 eyes received one or more sessions of photody-
namic therapy. Twenty-two out of 75 eyes received one 
or more sessions of focal laser treatment. There was one 
eye of a black patient which had received PDT, and intra-
vitreal injections with bevacizumab and triamcinolone 
Fig. 4 Multimodal imaging of the right eye of a 76-year-old Black female with polypoidal choroidal vasculopathy (PCV) who was followed for 
56 months. Best corrected visual acuity (BCVA) upon initial diagnosis with PCV was 20/125 (61 letters), and worsened to counting fingers at last 
follow up visit. Treatment included 6 intravitreal injections with ranibizumab. Indocyanine green angiography image is showing late choroidal 
staining consistent with polypoidal lesions within the macula and nasal to the optic nerve. Upper row: Indocyanine green angiography imaging 
demonstrated macular and extramacular polypoidal lesions. Lower row: Color fundus photograph shows orange subretinal nodule, intraretinal and 
subretinal hemorrhage. Optical coherence tomography cross sectional B-scan through the macular polypoidal lesions (upon presentation) is dem-
onstrating a large serous pigment epithelial detachment (PED) within the macula with associated subretinal fluid temporally and small temporal 
notch
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acetate. Pars plana vitrectomy was utilized after bevaci-
zumab injections in one eye of a black patient, in order to 
clear massive subretinal hemorrhage and vitreous hem-
orrhage. Table 3 summarizes these findings.
Multivariate analysis
There was a significant decrease in final VA of seven 
ETDRS letters with every decade increase in age start-
ing at 50 years (p = 0.005). Final VA was worse in males 
when compared to females (p = 0.042). Final VA was sig-
nificantly worse (by 18 letters) in Whites when compared 
to Blacks (p = 0.005). For every 10 letters worse in initial 
BCVA upon diagnosis with PCV, the final VA was worse 
by 6 letters (p  <  0.001). The location of the polypoidal 
lesion within the anatomic macula was associated with 
significant decrease of 14 letters in BCVA (p  =  0.02). 
The length of follow up was significantly associated with 
worse final visual outcome (p = 0.012). Final VA had no 
statistically significant correlation with the lens status 
(phakic versus pseudophakic), nor the different treat-
ment modalities which the patients had received. The 
R-squared for our multiple regression analysis was 0.55 
(55%), and the adjusted R-squared was 0.45 (45%). The 
multivariate analysis model results are further demon-
strated in Table 4.
Discussion
The term PCV was first coined by Yannuzzi in 1982 (Yan-
nuzzi LA. Idiopathic Polypoidal Choroidal Vasculopathy. 
Presented at the Macula Society Meeting in Miami, Flor-
ida). The features of PCV were later described in 1990 
[1]. Kleiner and associates used the terminology “poste-
rior uveal bleeding syndrome” to describe PCV [28]. Fur-
ther understanding of this peculiar entity has matured 
over the past three decades. Yannuzzi and colleagues 
diagnosed PCV in 7.8% of 167 consecutive patients with 
presumed neovascularized AMD in the United States 
[29]. Recently, Kuroda et al. [30] reported PCV in 52.5% 
of 343 eyes with neovascular AMD in Japan. Our retro-
spective multicenter study investigated the characteris-
tics and racial variations of PCV patients in three tertiary 
centers the United States and the United Kingdom, and 
evaluated the predictive factors that determine visual 
outcomes in those patients.
PCV involvement was reported to be mostly unilat-
eral (90% of patients) in a large Japanese cohort of 100 
patients with PCV [3]. Recently, Alasil et al. [9] demon-
strated choroidal vascular abnormalities in the unaf-
fected eyes of patients with PCV using en face prototype 
swept source OCT. In our cohort, PCV was found to be 
bilateral in about 20% of patients regardless of the ethnic 
Fig. 5 Fundus photographs and indocyanine green angiography (ICGA) imaging of a 50-year-old white woman with metabolic syndrome and 
bilateral polypoidal choroidal vasculopathy (PCV) who was followed for 104 months. Fundus photos show subretinal hemorrhage along the 
inferotemporal macula and inferotemporal arcade OD, and central macula scar with pigmentation OS. ICGA shows polypoidal lesions along the 
temporal macula adjacent to the area of submacular hemorrhage OD and a polyp along the nasal edge of the central macula scar OS. Best cor-
rected visual acuity (BCVA) upon initial diagnosis with PCV was 20/100 (65 letters) OD and counting fingers OS. Vision improved to 20/50 (80 letters) 
at last follow up visit OD after treatment with focal laser plus 12, 5 and 9 intravitreal injections with bevacizumab, ranibizumab and aflibercept, 
respectively. Left eye received no treatment and vision remained at counting fingers
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subgroup. PCV is usually diagnosed in patients between 
the ages of 50 and 65 years old. The average age of onset 
reported in the literature for PCV patients was 60 years 
[2]. White patients tend to present with PCV at an older 
age [28]. The mean age in our cohort was 69  years old, 
which can be explained by the different ethnicities 
included in the sample, including 22.5% white individu-
als. Final VA was decreased by seven ETDRS letters for 
every decade increase in age starting at 50 years.
Male preponderance was reported in multiple Asian 
PCV studies, including 63% of 100 Japanese patients, 
[3] 78.5% of 79 Korean patients, [31] and 68.4% of 19 
Fig. 6 Indocyanine green angiography (ICGA) and optical coherence tomography (OCT) imaging of a 71 year old Asian man with bilateral polypoi-
dal choroidal vasculopathy (PCV) who was followed for 35 months. Early and late ICGA images show central macular polyp OD and superior macula 
polypoidal lesion with central macular choroidal vascular dilation OS. Cross-sectional OCT scan images show pigment epithelial detachments, 
double layer sign (branching vascular network) and thick choroid in both eyes. Best corrected visual acuity (BCVA) upon initial diagnosis with PCV 
was 65 letters OD and 57 letters OS. Vision worsened to 12 letters at last follow up visit OD after treatment with 4 and 9 intravitreal injections with 
bevacizumab and aflibercept, respectively. Left eye received 4 and 10 intravitreal injections with bevacizumab and aflibercept respectively and 
vision improved to 66 letters
Table 1 Demographics of subjects with polypoidal choroidal vasculopathy included in the analysis
BCVA indicates Best corrected visual acuity (ETDRS letter count)
PCV indicates polypoidal choroidal vasculopathy
Number of subjects 80 eyes (71 patients) Mean age (years) 69.4 ± 10.4
Follow up (months) 31.8 ± 27.9
Mean BCVA Initial Last follow up
65.1 ± 19.1 63.0 ± 27.6
Mean change in BCVA −2.1 ± 24.2 (ETDRS Letters)
Gender 25 males (35%) 46 females (65%)
Lens status 66 phakic eyes (82.5%) 14 pseudophakic eyes (17.5%)
Ethnicity Asian Black White Other
Number of subjects 19 (26.8%) 33 (46.5%) 16 (22.5%) 3 (4.2%)
Gender (female/total) 11/19 (58%) 22/33 (67%) 11/16 (69%) 2/3 (67%)
Mean change in BCVA −2.3 ± 29.0 3.5 ± 18.2 −13.1 ± 26.9 2.3 ± 10
Mean age (years) 67.8 ± 9.2 71.1 ± 9.8 67.8 ± 13.3 67.7 ± 6.8
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Chinese patients [32]. On the other hand, the initial 
posterior uveal bleeding syndrome report described 
predominance in women over men in a small sample of 
black patients [28]. de Mello et  al. reported female pre-
ponderance (67% of 72 Brazilian patients) [33]. Hatz et al. 
[6] reported female preponderance (71% of 34 of Cauca-
sian Swiss patients with PCV). Davis et al. [34] reported 
female preponderance of 52% in 27 white patients with 
PCV in the United States. In our cohort, PCV featured 
a variable female predominance based on ethnicity (58% 
in Asians, 67% in Blacks and 69% in Whites). Our multi-
variate analysis suggested that final VA could be worse in 
males when compared to females in PCV. However, the 
p value of 0.042, the small sample size and the 2:1 female 
to male ratio make those gender-related conclusions 
uncertain.
A panel of PCV experts analyzed the body of literature 
on PCV together with results of the Everest trial, and 
made recommendations for the management of PCV 
which were based on this analysis and expert opinions 
[20]. Delivering PDT to the polypoidal lesions will result 
in occlusion of the polypoidal lesions and focal choroidal 
ischemia at the treated areas [35, 36], which may result 
in further VEGF secretion from the surrounding intact 
branching vascular network and subsequent recurrence 
of serosanguinous exudation causing further visual dete-
rioration. Hence, the benefits of combining PDT with 
intravitreal injections of anti-VEGF agents were strongly 
emphasized [20]. Focal laser can be utilized to target 
polypoidal lesions outside the central macula. However, it 
may cause progressive photoreceptor degeneration with 
fibrosis and atrophic changes in the area over the scar, 
resulting in no improvement or even worsening of VA. 
Our multivariate analysis showed no significant effects 
of different treatment modalities on BCVA, probably 
because our sample was mixed in regards to the treat-
ments delivered to the patients, and our retrospective 
study was not designed to examine the effects of different 
treatment modalities on visual outcomes in patients with 
PCV. As expected, the location of the polypoidal lesion 
Table 2 Location and laterality of polypoidal lesions on indocyanine green angiography of eyes with polypoidal choroi-
dal vasculopathy included in the analysis
Location of polypoidal lesions is based on indocyanine green angiography findings
Ethnicity Number of eyes Location of polyps Number of subjects Bilateral disease
Macular Extra-macular
Asians 23 18 (78.3%) 5 (21.7%) 19 4 (21%)
Blacks 36 25 (69.4%) 11 (30.6%) 33 7 (21%)
Whites 19 16 (84.2%) 3 (15.8%) 16 3 (19%)
Other 3 3 (100%) 0 3 0
Total 80 62 (77.5%) 18 (22.5%) 71 14 (20%)
Table 3 Treatment
PDT photodynamic therapy, VEGF vascular endothelial growth factor
Number of eyes
Total 80
Observation (no treatment) 5
Treatment 75
Treatment modalities PDT 12
Focal laser 22
Intravitreal injections  
with anti-VEGF agents
68
Total number of anti- 
VEGF injections
Bevacizumab Ranibizumab Aflibercept
109 injections 369 injections 198 injections
Intravitreal injection  
with triamcinolone
1
Pars plana vitrectomy 1
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within the anatomic macula was associated with worse 
visual outcome.
Final VA was significantly worse (by 16 letters) in 
Whites when compared to Blacks, but was not statisti-
cally different when Asians were compared to Blacks. 
Blacks were used as the reference group, because they 
were the largest ethnic subgroup in our cohort. This 
might very well be a random finding despite the p value, 
given the relatively small sample size, the Black group had 
twice as much extra-macular lesions compared with the 
White group, which could explain the visual outcome dif-
ferences. Nevertheless, PCV appears to have two forms: a 
subset of choroidal neovascularization from a variety of 
etiologies, most commonly related to neovascular age-
related macular degeneration (AMD); or a different dis-
ease from AMD which is usually encountered in darkly 
pigmented individuals, and without other characteristic 
fundus findings of AMD. However, there appears to be 
some overlapping features between these two entities.
The baseline BCVA upon initial diagnosis with PCV 
and the length of follow up were both found to be impor-
tant predictors of final VA. Traditionally, patients with 
active or poorly responding PCV lesions tend to fol-
low longer than patients who respond well to treat-
ment. The mean follow up for the patients in our cohort 
was 32  months, and the range varied between 2 and 
120 months. The relapsing-remitting nature of PCV may 
explain the lengthy follow up in some of our patients.
Our study has a number of strengths; in particular, the 
ICGA-confirmed PCV patients included in this study 
met the EVEREST inclusion criteria, were diverse and 
probably representative of subjects with PCV seen in 
the United Kingdom and United States. The sample size 
was relatively small compared to the studies from Japan, 
South Korea and Singapore. However, different ethnici-
ties were represented including Black, Asian and White 
individuals.
Our study also has a number of limitations related to its 
retrospective nature. There was variability in the follow 
up duration between patients. The centers participating 
in the study were tertiary referral centers. Our multi-
variate analysis r-squared result of 0.55 suggests that the 
model doesn’t explain well the observed data. The study 
was not specifically designed to evaluate the effects of 
ethnicity and different treatment modalities on the visual 
outcome in patients with PCV.
OCT angiography (OCTA) is a non-invasive imaging 
technology that can visualize the retinal and choroidal 
vasculature. This technology is increasingly being used 
to image CNV since it can visualize the neovascular 
complex both above and beneath the RPE [37, 38]. Fig-
ure 2 shows an example of OCTA imaging of polypoidal 
Table 4 Multiple linear regression of demographic and clinical variables: effect on best corrected visual acuity at last fol-
low up in patients with polypoidal choroidal vasculopathy
The dependent variable is best corrected visual acuity (BCVA) at last follow up visit documented as early treatment diabetic retinopathy study (ETDRS) letter count. 
The independent variables are age, gender, ethnicity, initial BCVA, follow up (months), polyp location, lens status, and different treatment modalities, including 
photodynamic therapy (PDT), focal laser, intravitreal injections with bevacizumab, ranibizumab, and aflibercept. R squared was 0.55 and adjusted R squared was 0.45
* Statistically significant p < 0.05
a Female was used as the reference group (dominant gender in our cohort)
b Black was used as the reference group (largest ethnic group in our cohort). All calculations were made based on a multivariate analysis model
Variables Coefficients Standard error t Stat p value Lower 95% Upper 95%
Age −0.71 0.25 −2.89 0.005* −1.21 −0.22
Gendera −10.75 5.19 −2.07 0.042* −21.12 −0.39
Ethnicityb
 Asian −9.424398 6.08 −1.55 0.16 −21.56 2.71
 White −18.07 6.18 −2.92 0.005* −30.41 −5.73
 Other 0.58 13.06 0.045 0.97 −25.51 26.67
Initial BCVA 0.58 0.14 4.27 <0.001* 0.31 0.85
Follow up −0.25 0.095 −2.6 0.012* −0.44 −0.06
Polyp location −14.41 6.00 −2.4 0.02* −26.39 −2.42
Lens status −0.96 6.94 −0.14 0.89 −14.83 12.91
Treatment
 PDT −2.15 5.66 −0.38 0.71 −13.45 9.15
 Focal laser 0.62 3.12 0.2 0.84 −5.61 6.84
 Bevacizumab 1.94 0.96 2.03 0.05 0.034 3.85
 Ranibizumab 0.65 0.4 1.64 0.11 −0.14 1.44
 Aflibercept 0.60 0.79 0.76 0.45 −0.98 2.19
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lesions and branching vascular network in PCV. Previous 
studies have shown that the branching vascular network 
can regularly be detected using OCTA [39, 40]. How-
ever, Kim et al. [39] showed that only 50% of the polyps 
could be identified using this imaging modality. It’s been 
hypothesized that a turbulent flow inside the polyp would 
not generate a decorrelation signal inside the threshold 
range of commercially available OCTA [40]. Therefore, 
we anticipate ICGA to remain the gold standard for mak-
ing the diagnosis of PCV and guiding the PDT treatment 
when indicated. In the future, the speed and resolution 
improvements in OCT angiography might provide an 
additional diagnostic and monitoring tool in PCV.
Conclusion
Based on our cohort from tertiary centers in the United 
States and United Kingdom, PCV is a bilateral disease 
in 20% of patients. It features a variable female predomi-
nance based on ethnicity. The following co-variables 
are significantly associated with worse VA outcomes: 
increased age, worse vision upon initial presentation, 
longer follow up and macular location of the polyp.
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